Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Patent
1995-06-07
1998-07-07
Schwadron, Ronald B.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
424 149, 4241431, 4241441, 4241531, 4241551, 4241731, 4241741, 424800, 424801, 4353201, 435344, 4353441, 435328, 5303873, 53038822, 53038873, 5303888, 5303897, 5303913, 530809, 530867, 935 89, 935104, 935107, A61K 39395, A61K 5100, C07K 1628, C07K 1630
Patent
active
057764565
ABSTRACT:
Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.
REFERENCES:
patent: 5500362 (1996-03-01), Robinson et al.
Reff et al., J. Cell. Biochen., 17, Suppl. E., 1993, Abstract T 103.
Tedder, T.F. 16 Eur. J. Immunol. 881 (1986).
Valentine, M.A. 264/19 J.Bio. Chem. 11282 (1989).
Ozato, K. 126/1 J. Immunol. 317 (1981).
Calvert, J.E. 21/4 Sem Hema. 226 (1984).
Anderson, K.C. 63/6 Blood 1424 (1984).
Oettgen, H.C. 2/1 Hybridoma 17 (1983).
Lipton, J.M. 60/1 Blood 170a (Abs. 609) (1982).
Anderson, K.C. 69/2 Blood 597 (1987).
Adams, R.A. 27/1 Can. Res. 2479 (1967).
Adams, R.A. 28 Can Res. 1121 (1968).
Smeland, E.B. 13810 J. Immunol. 3179 (1987).
Nadler, L.M. 74 J.Clin. Ivest. 332 (1984).
Bhan, A.K. 154 J. Exp. Med. 737 (1981).
Reff, M.E. 83/2 Blood 435 (1994).
Buchsbaum, D.J. 25 Int. J. Radiation Onc. Bio Phys. 629 (1993).
Buchsbaum, D.J. 50 Can. Res. Supp. 9935 (1990).
Buchsbaum, D.J. 18 Int. J. Radiation Onc. Bio Phys. 1033 (1990).
Schlum, J. 82/9 J.N.C.I. 763 (1990).
Wessel, B.W. 11/5 Med. Phys. 638 (1984).
Srivastava, S.C. 18/6 Nucl. Med. Biol. 589 (1991).
DeNardo, S.J. 1/1 Antibody, Immuno. & Radiopharm. 17 (1988).
Appelbaum, F.R. 5/5 Hem./Onc. Clinics of N.A. 1013 (1991).
Eary, J.F. 31/8 J. Nucl. Med. 1257 (1990).
Press, O.W. 7/8 J. Clin. Onc. 1027 (1989).
Goldenberg, D.M. 9/4 J. Clin. Onc. 548 (1991).
"Antibody shows promise in treating B-cell lymphoma", Cope-Working In Oncology, (Mar./ Apr. 1994).
Anderson, D.R., The Second Annual IBC International Conference on Antibody Engineering, (Dec. 16-18, 1991).
Press, O.W. 69/2 Blood 584 (1987).
Liu, A.Y. 13910 J. Immunol. 3521 (1987).
Robinson, R.R. 2 Hum. Antibod. Hybrid. 84 (1991).
Morrison, S.L. 81 PNAS 6851 (1984).
Boulianne, G.L. 312 Nature 643 (1984).
Neubeiger,M.D. 314 Nature 268 (1985).
Tan, L.K. 135 J. Immunol. 8564 (1985).
Sun, L.K. 5/1 Hybridoma 517 (1986).
Sahagan, B.G. 137 J. Immunol. 1066 (1986).
Munro, A. 312 Nature 597 (1984).
Dickson 5/3 Genetic Engineering News (1985).
Marx 229 Science 455 (1985).
Morrison 229 Science 1202 (1985).
Grossbard, M.L. 80/4 Blood 863 (1992).
Clark, E. 82 PNAS 1766 (1985).
Robertson, M.J. 79/9 Blood 2229 (1992).
Nadler, L.M. The Lancet 427 (Aug. 25, 1984).
Golay, J.T. 135/6 J. Immunol. 3795 (1985).
Greenberger, J.S. 45 Can. Res. 758 (1985).
Nadler, L.M. 40 Can. Res. 3147 (1980).
Teddler, T.F. 14112 J. Immunol 4388 (1988).
Einfeld, D.A. 7/3 The EMBO Journal 711 (1988).
Teddler, T.F. 1352 J. Immunol. 973 (1985).
Anderson Darrell R.
Hanna Nabil
Leonard John E.
Newman Roland A.
Rastetter William H.
Idec Pharmaceuticals Corporation
Schwadron Ronald B.
LandOfFree
Therapeutic application of chimeric and radiolabeled antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic application of chimeric and radiolabeled antibodies , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic application of chimeric and radiolabeled antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1202563